智通财经网·2025-10-28 13:05Core Viewpoint - The company, Kanglong Chemical (03759), has announced an agreement to acquire 82.54% of Baiaode for approximately RMB 1.346 billion, which will make Baiaode a subsidiary of the company [1][2]. Group 1: Acquisition Details - The acquisition will result in Baiaode being directly held by the company, enhancing its position in the innovative drug research and development sector [2]. - Baiaode specializes in drug discovery services based on complex drug target protein preparation, with a focus on structural biology and advantages in cryo-electron microscopy [2][3]. - The acquisition is expected to strengthen the company's biological science service capabilities and enhance its leadership in the global early biological science service sector [2]. Group 2: Synergies and Capabilities - Baiaode possesses advanced hardware and a research team with extensive experience in protein preparation, which will complement the company's large molecule business segment [3]. - The integration of Baiaode's capabilities in complex protein preparation and structural analysis will enhance the company's early antibody discovery and optimization capabilities [3]. - The acquisition will also allow for the sharing of data between Baiaode and the company, leveraging AI technology for improved drug discovery efficiency [3]. Group 3: Financial Impact - Following the acquisition, Baiaode will be consolidated into the company's financial statements using the cost method, which is expected to positively impact the company's operating performance [4]. - The company anticipates that the acquisition will have a short-term and manageable impact on its finances, with the potential for sustainable bank loans based on Baiaode's profitability and debt repayment capacity [4].